Articles related to CLINICAL STUDY

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

Smartwatch-derived nighttime scratching metrics correlated moderately with disease severity and short-term treatment response in a small pediatric atopic dermatitis cohort.

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.

“It’s essentially the same as proving that it’s OK for babies to play with matches, but only if there’s nothing flammable in the area and they’re wearing fireproof clothing.” – William Parker, on over-adjustment in sibling studies

“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”

“Mean LOS post-transplant was significantly shorter in the post-APP cohort (P = .005). The mean LOS for the pre- and post-APP cohorts were 22.4 and 16.5 days, respectively.”